Fadi Al-Khayer, MD
Endocrinology, Diabetes & Metabolism · Storrs, CTNPI 1861477069
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $433,557 of the $488,989 with a category attached, or 88.7%. 18 manufacturers reported payments, led by Lilly USA, LLC at 29.5% of the total. Among endocrinology, diabetes & metabolism clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 713 payments — averaging $685.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$144K
- Corcept Therapeutics$143K
- Novo Nordisk$124K
- AstraZeneca$56K
- Johnson & Johnson$16K
- AbbVie$5K
- plus $731 from 12 others
What the payments were for
- Consulting fees$12,1102%
- Speaking & faculty fees$433,55789%
- Travel & lodging$26,4315%
- Food & beverage$16,7793%
- Education$1130%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 291 | $144,476 |
| Corcept Therapeutics | 174 | $142,708 |
| Novo Nordisk | 115 | $124,403 |
| AstraZeneca(2 entities) | 75 | $55,843 |
| Johnson & Johnson | 18 | $15,690 |
| AbbVie | 18 | $5,137 |
| Xeris Pharmaceuticals, Inc. | 8 | $332 |
| Kyowa Kirin, Inc. | 1 | $125 |
| Amgen | 3 | $58 |
| Abbott | 2 | $34 |
| Lexicon Pharmaceuticals, Inc. | 1 | $29 |
| Insulet Corporation | 1 | $27 |
| Almatica Pharma LLC | 1 | $26 |
| Senseonics, Incorporated | 1 | $23 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $21 |
| Intra-sana Laboratories | 1 | $21 |
| Recordati_rare_diseases_inc. | 1 | $17 |
| Bayer | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$488,989 in reported general payments places this provider in the 95th percentile of 177 endocrinology, diabetes & metabolism providers in Connecticut.
See all endocrinology, diabetes & metabolism providers in Connecticut →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KorlymMifepristone | 53 | $1,666,597 |
| MounjaroTirzepatide | 530 | $677,464 |
| OzempicSemaglutide | 400 | $547,283 |
| FarxigaDapagliflozin Propanediol | 201 | $236,698 |
| Teriparatide | 47 | $129,017 |
| JardianceEmpagliflozin | 77 | $101,064 |
| SynthroidLevothyroxine Sodium | 862 | $92,375 |
| Evenity (2 Syringes)Romosozumab-Aqqg | 35 | $85,469 |
| Tresiba Flextouch U-100Insulin Degludec | 95 | $61,326 |
| Tresiba Flextouch U-200Insulin Degludec | 34 | $54,489 |
| Xigduo XrDapaglifloz Propaned/Metformin | 37 | $40,635 |
| WegovySemaglutide | 19 | $30,845 |
| TrulicityDulaglutide | 23 | $29,416 |
| JanuviaSitagliptin Phosphate | 35 | $24,338 |
| Repatha SureclickEvolocumab | 14 | $22,486 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Corcept TherapeuticsKorlym | $142,708 | $1,666,59753 claims |
| Lilly USA, LLCMounjaro, Trulicity, Baqsimi, Humalog, Lyumjev | $144,476 | $721,641589 claims |
| Novo NordiskOzempic, Wegovy, Novolog | $124,403 | $589,742455 claims |
| AstraZenecaFarxiga | $55,843 | $236,698201 claims |
| AmgenEvenity (2 Syringes), Prolia | $58 | $105,38447 claims |
| AbbVieSynthroid, Armour Thyroid | $5,137 | $97,113918 claims |
| BayerKerendia | $17 | $19,29719 claims |
| Johnson & JohnsonInvokana | $15,690 | $12,14315 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 177 endocrinology, diabetes & metabolism providers in Connecticut.
Other endocrinology, diabetes & metabolism in Storrs
- Egils BogdanovicsTorrington$608K
- Ania JastreboffNew Haven$536K
- Robert ObersteinHartford$516K
- Silvio InzucchiNew Haven$461K
- Philip GoldbergNew Haven$324K
- Kevan HeroldNew Haven$261K
- Joseph RosenblattNew Britain$235K
- David DomenichiniBloomfield$220K
- Glenn RichTrumbull$210K
- Gerald ShulmanNew Haven$194K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.